ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

ClinicalTrials.gov ID: NCT02798211

Public ClinicalTrials.gov record NCT02798211. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 6:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis After 16 Weeks of Treatment Compared to Placebo and to Assess the Safety, Tolerability and Efficacy up to 52 Weeks

Study identification

NCT ID
NCT02798211
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
258 participants

Conditions and interventions

Interventions

  • Placebo Other
  • Secukinumab 150 mg Drug
  • Secukinumab 300 mg Drug

Other · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 26, 2016
Primary completion
Dec 4, 2018
Completion
Dec 4, 2018
Last update posted
Oct 6, 2021

2016 – 2018

United States locations

U.S. sites
57
U.S. states
21
U.S. cities
54
Facility City State ZIP Site status
Novartis Investigative Site Birmingham Alabama 35205
Novartis Investigative Site Little Rock Arkansas 72205
Novartis Investigative Site El Cajon California 92020
Novartis Investigative Site Fountain Valley California 92708
Novartis Investigative Site La Jolla California 92093
Novartis Investigative Site La Mesa California 91942
Novartis Investigative Site Upland California 91786
Novartis Investigative Site Aventura Florida 33180
Novartis Investigative Site Clearwater Florida 33765
Novartis Investigative Site DeBary Florida 32713
Novartis Investigative Site Jacksonville Florida 32207
Novartis Investigative Site North Naples Florida 34102
Novartis Investigative Site Palm Harbor Florida 34684
Novartis Investigative Site Pensacola Florida 32514
Novartis Investigative Site Plantation Florida 33324
Novartis Investigative Site Sarasota Florida 34239
Novartis Investigative Site Tampa Florida 33609
Novartis Investigative Site Tampa Florida 33613
Novartis Investigative Site Duluth Georgia 30096
Novartis Investigative Site Baltimore Maryland 21224
Novartis Investigative Site Boston Massachusetts 02115
Novartis Investigative Site Worcester Massachusetts 01655
Novartis Investigative Site Battle Creek Michigan 49015
Novartis Investigative Site Kalamazoo Michigan 49008
Novartis Investigative Site Eagan Minnesota 55121
Novartis Investigative Site Lincoln Nebraska 68516
Novartis Investigative Site Las Vegas Nevada 89106
Novartis Investigative Site Ridgewood New Jersey 07450
Novartis Investigative Site Summit New Jersey 07901
Novartis Investigative Site Albany New York 12206
Novartis Investigative Site Brooklyn New York 11201
Novartis Investigative Site Lake Success New York 11402
Novartis Investigative Site Orchard Park New York 14127
Novartis Investigative Site Potsdam New York 13676
Novartis Investigative Site Saranac Lake New York 12983
Novartis Investigative Site Charlotte North Carolina 28226
Novartis Investigative Site Greensboro North Carolina 27408
Novartis Investigative Site New Bern North Carolina 28562
Novartis Investigative Site Marion Ohio 43302
Novartis Investigative Site Perrysburg Ohio 43551
Novartis Investigative Site Duncansville Pennsylvania 16635
Novartis Investigative Site Philadelphia Pennsylvania 19104
Novartis Investigative Site Charleston South Carolina 29460
Novartis Investigative Site Greenville South Carolina 29601
Novartis Investigative Site Orangeburg South Carolina 29118-2475
Novartis Investigative Site Jackson Tennessee 38305
Novartis Investigative Site Arlington Texas 76014
Novartis Investigative Site Arlington Texas 77373
Novartis Investigative Site Austin Texas 78731
Novartis Investigative Site Dallas Texas 75231
Novartis Investigative Site Dallas Texas 75246
Novartis Investigative Site Houston Texas 77074
Novartis Investigative Site Mesquite Texas 75150
Novartis Investigative Site San Antonio Texas 78229
Novartis Investigative Site Salt Lake City Utah 84132
Novartis Investigative Site Seattle Washington 98122
Novartis Investigative Site Spokane Washington 99204

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02798211, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 6, 2021 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02798211 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →